Dermatology
| Psoriasis
Dermatology
Psoriasis
COVID-19-related adverse events in the phase 3 POETYK Trials of the allosteric TYK2 inhibitor, deucravacitinib, in patients with moderate to severe plaque psoriasis
book_2
Source:
EADV Congress 2022 - Oral session
calendar_today
Published on Medfyle:
September 2022
import_contacts
4
min
In this medfyle
Clinical trials were complicated by the COVID-19 pandemic, but this analysis of POETYK finds deucravacitinib did not appear to increase the risk of COVID-19 nor progression to severe outcomes.
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
About this Medfyle
Read more
arrow_downward
Hide
arrow_upward
This is a highlights summary of an oral session given at the EADV 2022 - 31st Congress and presented by:
Professor Dr. Diamant Thaçi
University of Lübeck
Lübeck, Germany
The content is produced by Infomedica, the official reporting partner of EADV 2022.
The presenting authors of the original session had no part in the creation of this conference highlights summary.
